Having studied for a degree in Biochemistry and a PhD in Cell Biology, Anthony spent his early career in drug discovery research in academia and the pharmaceutical industry. Anthony entered the ATMPs field in 2009 through a role at UCL Institute of Ophthalmology’s clinical cell therapy unit. He then worked as a regulatory consultant focusing on CMC for ATMPs at ERA Consulting in London, where he was involved in the successful Marketing Authorisation Application for Chiesi’s tissue-engineered product, Holoclar. Anthony moved to Italy to join Chiesi in June 2016, working on post-authorisation CMC submissions for Holoclar, the MAA for an orphan enzyme replacement therapy, and three clinical-stage ATMP programmes. Anthony joined Kite in July 2018 where he is currently EU CMC-Regulatory Lead for the authorised CAR-T product, Yescarta, and other CAR-T therapies in development.